Review





Similar Products

90
Zymo Research target captured dna
Target Captured Dna, supplied by Zymo Research, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/target captured dna/product/Zymo Research
Average 90 stars, based on 1 article reviews
target captured dna - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

94
TaKaRa 3 feature barcode capture sequence
3 Feature Barcode Capture Sequence, supplied by TaKaRa, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/3 feature barcode capture sequence/product/TaKaRa
Average 94 stars, based on 1 article reviews
3 feature barcode capture sequence - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

95
Broad Clinical Labs whole exome capture
Whole Exome Capture, supplied by Broad Clinical Labs, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/whole exome capture/product/Broad Clinical Labs
Average 95 stars, based on 1 article reviews
whole exome capture - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

93
Arima Genomics Inc chromatin conformation capture sequencing hi c libraries
Chromatin Conformation Capture Sequencing Hi C Libraries, supplied by Arima Genomics Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/chromatin conformation capture sequencing hi c libraries/product/Arima Genomics Inc
Average 93 stars, based on 1 article reviews
chromatin conformation capture sequencing hi c libraries - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

90
MyGenostics Inc hbv capture sequencing
A Map of the CCDC91 gene with <t>HBV</t> DNA insertion in HCC (n = 17) and NHL (n = 1) tissues. Black arrows indicate HBV integration sites identified through pooled-analysis in HCC. Red arrows represent HBV integration sites detected in HCC samples using our HBV capture <t>sequencing</t> approach. Blue arrows denote HBV integration sites identified in non-Hodgkin lymphoma (NHL) samples from our previous HBV capture sequencing study. B Immunohistochemistry staining showed the protein expression of CCDC91 in 4 HBV capture sequencing HCC tissues. C The mRNA levels of CCDC91 in HCC tissues and non-cancerous liver tissues from GSEA cohorts ( GSE36376 : n = 193 in non-tumor, n = 240 in tumor; GSE76427 : n = 52 in non-tumor, n = 115 in tumor). D The mRNA levels of CCDC91 in HCC tissues and non-cancerous liver tissues from TCGA cohort (n = 50 in non-tumor, n = 371 in tumor). E Relative mRNA levels of CCDC91 in HCC cells as determined by qPCR (n = 3 independent biological repeats). F Representative IHC images of CCDC91 in HCC tissues and adjacent paratumor tissues (left) and IHC scores of CCDC91 staining in HCC tissues and non-cancerous liver tissues (right, n = 123). G The Kaplan–Meier analysis and log-rank test revealed the association of CCDC91 with the overall survival of HCC patients from TCGA dataset. H Multivariate logistic regression analyses for the associations of CCDC91 expression in HCC patients from TCGA dataset (n = 240). I Multivariate Cox regression analysis of the data from the TCGA dataset revealed that CCDC91 was an independent predictor of OS (n = 120). J The Kaplan–Meier analysis and log-rank test revealed the association of CCDC91 with the overall survival of HCC patients from TMA cohort (n = 123). K Multivariate logistic regression analyses for the associations of CCDC91 expression in HCC patients from TMA cohort (n = 80). Statistical analysis was performed using Student’s t test in ( C , D , E , and F ). Error bars represent the SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001.
Hbv Capture Sequencing, supplied by MyGenostics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hbv capture sequencing/product/MyGenostics Inc
Average 90 stars, based on 1 article reviews
hbv capture sequencing - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
10X Genomics 10x genomics capture sequences cs1
A Map of the CCDC91 gene with <t>HBV</t> DNA insertion in HCC (n = 17) and NHL (n = 1) tissues. Black arrows indicate HBV integration sites identified through pooled-analysis in HCC. Red arrows represent HBV integration sites detected in HCC samples using our HBV capture <t>sequencing</t> approach. Blue arrows denote HBV integration sites identified in non-Hodgkin lymphoma (NHL) samples from our previous HBV capture sequencing study. B Immunohistochemistry staining showed the protein expression of CCDC91 in 4 HBV capture sequencing HCC tissues. C The mRNA levels of CCDC91 in HCC tissues and non-cancerous liver tissues from GSEA cohorts ( GSE36376 : n = 193 in non-tumor, n = 240 in tumor; GSE76427 : n = 52 in non-tumor, n = 115 in tumor). D The mRNA levels of CCDC91 in HCC tissues and non-cancerous liver tissues from TCGA cohort (n = 50 in non-tumor, n = 371 in tumor). E Relative mRNA levels of CCDC91 in HCC cells as determined by qPCR (n = 3 independent biological repeats). F Representative IHC images of CCDC91 in HCC tissues and adjacent paratumor tissues (left) and IHC scores of CCDC91 staining in HCC tissues and non-cancerous liver tissues (right, n = 123). G The Kaplan–Meier analysis and log-rank test revealed the association of CCDC91 with the overall survival of HCC patients from TCGA dataset. H Multivariate logistic regression analyses for the associations of CCDC91 expression in HCC patients from TCGA dataset (n = 240). I Multivariate Cox regression analysis of the data from the TCGA dataset revealed that CCDC91 was an independent predictor of OS (n = 120). J The Kaplan–Meier analysis and log-rank test revealed the association of CCDC91 with the overall survival of HCC patients from TMA cohort (n = 123). K Multivariate logistic regression analyses for the associations of CCDC91 expression in HCC patients from TMA cohort (n = 80). Statistical analysis was performed using Student’s t test in ( C , D , E , and F ). Error bars represent the SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001.
10x Genomics Capture Sequences Cs1, supplied by 10X Genomics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/10x genomics capture sequences cs1/product/10X Genomics
Average 90 stars, based on 1 article reviews
10x genomics capture sequences cs1 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Illumina Inc hybrid capture-based targeted next-generation sequencing ngs
A Map of the CCDC91 gene with <t>HBV</t> DNA insertion in HCC (n = 17) and NHL (n = 1) tissues. Black arrows indicate HBV integration sites identified through pooled-analysis in HCC. Red arrows represent HBV integration sites detected in HCC samples using our HBV capture <t>sequencing</t> approach. Blue arrows denote HBV integration sites identified in non-Hodgkin lymphoma (NHL) samples from our previous HBV capture sequencing study. B Immunohistochemistry staining showed the protein expression of CCDC91 in 4 HBV capture sequencing HCC tissues. C The mRNA levels of CCDC91 in HCC tissues and non-cancerous liver tissues from GSEA cohorts ( GSE36376 : n = 193 in non-tumor, n = 240 in tumor; GSE76427 : n = 52 in non-tumor, n = 115 in tumor). D The mRNA levels of CCDC91 in HCC tissues and non-cancerous liver tissues from TCGA cohort (n = 50 in non-tumor, n = 371 in tumor). E Relative mRNA levels of CCDC91 in HCC cells as determined by qPCR (n = 3 independent biological repeats). F Representative IHC images of CCDC91 in HCC tissues and adjacent paratumor tissues (left) and IHC scores of CCDC91 staining in HCC tissues and non-cancerous liver tissues (right, n = 123). G The Kaplan–Meier analysis and log-rank test revealed the association of CCDC91 with the overall survival of HCC patients from TCGA dataset. H Multivariate logistic regression analyses for the associations of CCDC91 expression in HCC patients from TCGA dataset (n = 240). I Multivariate Cox regression analysis of the data from the TCGA dataset revealed that CCDC91 was an independent predictor of OS (n = 120). J The Kaplan–Meier analysis and log-rank test revealed the association of CCDC91 with the overall survival of HCC patients from TMA cohort (n = 123). K Multivariate logistic regression analyses for the associations of CCDC91 expression in HCC patients from TMA cohort (n = 80). Statistical analysis was performed using Student’s t test in ( C , D , E , and F ). Error bars represent the SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001.
Hybrid Capture Based Targeted Next Generation Sequencing Ngs, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hybrid capture-based targeted next-generation sequencing ngs/product/Illumina Inc
Average 90 stars, based on 1 article reviews
hybrid capture-based targeted next-generation sequencing ngs - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Twist Bioscience sequence of probes of the capture
A Map of the CCDC91 gene with <t>HBV</t> DNA insertion in HCC (n = 17) and NHL (n = 1) tissues. Black arrows indicate HBV integration sites identified through pooled-analysis in HCC. Red arrows represent HBV integration sites detected in HCC samples using our HBV capture <t>sequencing</t> approach. Blue arrows denote HBV integration sites identified in non-Hodgkin lymphoma (NHL) samples from our previous HBV capture sequencing study. B Immunohistochemistry staining showed the protein expression of CCDC91 in 4 HBV capture sequencing HCC tissues. C The mRNA levels of CCDC91 in HCC tissues and non-cancerous liver tissues from GSEA cohorts ( GSE36376 : n = 193 in non-tumor, n = 240 in tumor; GSE76427 : n = 52 in non-tumor, n = 115 in tumor). D The mRNA levels of CCDC91 in HCC tissues and non-cancerous liver tissues from TCGA cohort (n = 50 in non-tumor, n = 371 in tumor). E Relative mRNA levels of CCDC91 in HCC cells as determined by qPCR (n = 3 independent biological repeats). F Representative IHC images of CCDC91 in HCC tissues and adjacent paratumor tissues (left) and IHC scores of CCDC91 staining in HCC tissues and non-cancerous liver tissues (right, n = 123). G The Kaplan–Meier analysis and log-rank test revealed the association of CCDC91 with the overall survival of HCC patients from TCGA dataset. H Multivariate logistic regression analyses for the associations of CCDC91 expression in HCC patients from TCGA dataset (n = 240). I Multivariate Cox regression analysis of the data from the TCGA dataset revealed that CCDC91 was an independent predictor of OS (n = 120). J The Kaplan–Meier analysis and log-rank test revealed the association of CCDC91 with the overall survival of HCC patients from TMA cohort (n = 123). K Multivariate logistic regression analyses for the associations of CCDC91 expression in HCC patients from TMA cohort (n = 80). Statistical analysis was performed using Student’s t test in ( C , D , E , and F ). Error bars represent the SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001.
Sequence Of Probes Of The Capture, supplied by Twist Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sequence of probes of the capture/product/Twist Bioscience
Average 90 stars, based on 1 article reviews
sequence of probes of the capture - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


A Map of the CCDC91 gene with HBV DNA insertion in HCC (n = 17) and NHL (n = 1) tissues. Black arrows indicate HBV integration sites identified through pooled-analysis in HCC. Red arrows represent HBV integration sites detected in HCC samples using our HBV capture sequencing approach. Blue arrows denote HBV integration sites identified in non-Hodgkin lymphoma (NHL) samples from our previous HBV capture sequencing study. B Immunohistochemistry staining showed the protein expression of CCDC91 in 4 HBV capture sequencing HCC tissues. C The mRNA levels of CCDC91 in HCC tissues and non-cancerous liver tissues from GSEA cohorts ( GSE36376 : n = 193 in non-tumor, n = 240 in tumor; GSE76427 : n = 52 in non-tumor, n = 115 in tumor). D The mRNA levels of CCDC91 in HCC tissues and non-cancerous liver tissues from TCGA cohort (n = 50 in non-tumor, n = 371 in tumor). E Relative mRNA levels of CCDC91 in HCC cells as determined by qPCR (n = 3 independent biological repeats). F Representative IHC images of CCDC91 in HCC tissues and adjacent paratumor tissues (left) and IHC scores of CCDC91 staining in HCC tissues and non-cancerous liver tissues (right, n = 123). G The Kaplan–Meier analysis and log-rank test revealed the association of CCDC91 with the overall survival of HCC patients from TCGA dataset. H Multivariate logistic regression analyses for the associations of CCDC91 expression in HCC patients from TCGA dataset (n = 240). I Multivariate Cox regression analysis of the data from the TCGA dataset revealed that CCDC91 was an independent predictor of OS (n = 120). J The Kaplan–Meier analysis and log-rank test revealed the association of CCDC91 with the overall survival of HCC patients from TMA cohort (n = 123). K Multivariate logistic regression analyses for the associations of CCDC91 expression in HCC patients from TMA cohort (n = 80). Statistical analysis was performed using Student’s t test in ( C , D , E , and F ). Error bars represent the SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001.

Journal: Communications Biology

Article Title: HBV DNA integration gene CCDC91 is oncogenic and a potential therapeutic target for hepatocellular carcinoma

doi: 10.1038/s42003-025-08369-1

Figure Lengend Snippet: A Map of the CCDC91 gene with HBV DNA insertion in HCC (n = 17) and NHL (n = 1) tissues. Black arrows indicate HBV integration sites identified through pooled-analysis in HCC. Red arrows represent HBV integration sites detected in HCC samples using our HBV capture sequencing approach. Blue arrows denote HBV integration sites identified in non-Hodgkin lymphoma (NHL) samples from our previous HBV capture sequencing study. B Immunohistochemistry staining showed the protein expression of CCDC91 in 4 HBV capture sequencing HCC tissues. C The mRNA levels of CCDC91 in HCC tissues and non-cancerous liver tissues from GSEA cohorts ( GSE36376 : n = 193 in non-tumor, n = 240 in tumor; GSE76427 : n = 52 in non-tumor, n = 115 in tumor). D The mRNA levels of CCDC91 in HCC tissues and non-cancerous liver tissues from TCGA cohort (n = 50 in non-tumor, n = 371 in tumor). E Relative mRNA levels of CCDC91 in HCC cells as determined by qPCR (n = 3 independent biological repeats). F Representative IHC images of CCDC91 in HCC tissues and adjacent paratumor tissues (left) and IHC scores of CCDC91 staining in HCC tissues and non-cancerous liver tissues (right, n = 123). G The Kaplan–Meier analysis and log-rank test revealed the association of CCDC91 with the overall survival of HCC patients from TCGA dataset. H Multivariate logistic regression analyses for the associations of CCDC91 expression in HCC patients from TCGA dataset (n = 240). I Multivariate Cox regression analysis of the data from the TCGA dataset revealed that CCDC91 was an independent predictor of OS (n = 120). J The Kaplan–Meier analysis and log-rank test revealed the association of CCDC91 with the overall survival of HCC patients from TMA cohort (n = 123). K Multivariate logistic regression analyses for the associations of CCDC91 expression in HCC patients from TMA cohort (n = 80). Statistical analysis was performed using Student’s t test in ( C , D , E , and F ). Error bars represent the SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001.

Article Snippet: HBV capture sequencing was conducted by MyGenostics (Beijing, China).

Techniques: Sequencing, Immunohistochemistry, Staining, Expressing